Effects of Hydroxyurea on IUdR Uptake in Cancer Patients
Author Information
Author(s): P.A. Philip, L. Kaklamanis, J. Carmichael, K. Tonkin, H. Morrison, K. Gatter, A.L. Harris
Primary Institution: Imperial Cancer Research Fund, Clinical Oncology Unit, Churchill Hospital, Oxford
Hypothesis
Can hydroxyurea improve the selective uptake of toxic thymidine analogues by resistant tumor cells?
Conclusion
Hydroxyurea significantly inhibits the incorporation of IUdR by both bone marrow and tumor cells.
Supporting Evidence
- Hydroxyurea was administered as a continuous intravenous infusion.
- Mean plasma concentrations of hydroxyurea were 1.7 mM at the time of IUdR administration.
- Uptake of IUdR was significantly lower in patients treated with hydroxyurea compared to those who were not.
Takeaway
This study shows that a drug called hydroxyurea can stop cancer cells from taking in a special marker, which helps doctors understand how well treatments are working.
Methodology
25 patients with various malignancies received IUdR after hydroxyurea infusion, and the uptake was measured immunocytochemically.
Limitations
The study had a small sample size and focused on specific types of cancer.
Participant Demographics
Mean age of patients was 60.3 years, with a gender ratio of 4 males to 10 females in the hydroxyurea group.
Statistical Information
P-Value
<0.005
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website